Skip to main content
Article thumbnail
Location of Repository

Review of olanzapine in the management of bipolar disorders

By Meera Narasimhan, Travis O Bruce and Prakash Masand

Abstract

Olanzapine is an atypical antipsychotic currently with indications for the treatment of schizophrenia, acute mania and the prevention of relapse in bipolar disorder. A growing body of clinical evidence supports these indications. Acute mania trials have demonstrated superior efficacy of olanzapine to placebo, equal or superior efficacy to valproate and superior efficacy in combination therapy with lithium or valproate compared to mood stabilizer monotherapy. Olanzapine demonstrated a modest effect in the treatment of bipolar depression with a substantially enhanced effect in combination with fluoxetine. Maintenance trials showed olanzapine to be more efficacious than placebo in the prevention of manic and depressive relapses and non-inferior to lithium or valproate. Combination of olanzapine with lithium or valproate was also found to be more efficacious than lithium or valproate monotherapy in the prevention of manic relapse in patients with a partial response to monotherapy with lithium or valproate. These trials suggest that olanzapine is a viable option and an invaluable addition to the pharmacological armamentarium in the treatment of bipolar I disorder. However, this can often be mitigated by safety and tolerability concerns with this agent including weight gain and metabolic syndrome that warrants clinician vigilance and discernment that is imperative in today’s clinical practice

Topics: Reviews
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2656294
Provided by: PubMed Central

Suggested articles

Citations

  1. (2003). A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.
  2. (2006). A 7-week, randomized, double-blind trial of olanzapine/fl uoxetine combination versus lamotrigine in the treatment of bipolar i depression.
  3. (2005). A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res,
  4. (2002). A comparison of the effi cacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.
  5. (2001). A review of the health-related quality of life literature in bipolar disorder. Qual Life Res,
  6. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
  7. (2003). Acute and maintenance treatment with mood stabilizers.
  8. (2003). Acute dysphoric mania: treatment response to olanzapine versus placebo.
  9. (2006). An update on the role of psychotherapy in the management of bipolar disorder. Curr Psychiatry Rep,
  10. (2005). Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients. Int Clin Psychopharmacol,
  11. (2005). Bipolar disorder and healthrelated quality of life: review of burden of disease and clinical trials.
  12. (2002). Correlates of overweight and obesity in 644 patients with bipolar disorder.
  13. (2006). Current schizophrenia drugs: effi cacy and side effects. Expert Opin Pharmacother,
  14. (2004). Diabetes Association.
  15. (1997). Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos,
  16. (2005). Drug-induced weight gain. Drugs Today (Barc),
  17. (2006). Early predictors of substantial weight gain in bipolar patients treated with olanzapine.
  18. (2002). Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial.
  19. (2005). Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.
  20. (2003). Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation.
  21. (2003). Effi cacy of olanzapine and olanzapine-fl uoxetine combination in the treatment of bipolar I depression.
  22. (2000). Effi cacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study.
  23. (2002). Effi cacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry,
  24. (2004). Expert consensus guideline series: treatment of bipolar disorder 2004. Postgraduate Med Special Report,
  25. (1997). In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
  26. (2005). Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
  27. (2005). Metabolic syndrome in bipolar disorder: fi ndings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord,
  28. (2003). Obesity as a correlate of outcome in patients with bipolar I disorder.
  29. (1999). Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. International Clinical Psychopharmacology,
  30. (2002). Olanzapine versus divalproex in the treatment of acute mania.
  31. (2003). Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.
  32. (2002). Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol,
  33. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
  34. (2005). Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.
  35. (1999). Olanzapine versus placebo in the treatment of acute mania.
  36. (2000). Olanzapine-induced acute pancreatitis. The Annals of Pharmacotherapy,
  37. (2004). Olanzapine-induced pancreatitis: a case report.
  38. (1999). Olanzapine: pharmacokinetic and pharmacodynamic profi le.
  39. (2003). Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association
  40. (2006). Psychiatric Association.
  41. (2006). Randomized, placebocontrolled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.
  42. (2004). Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.
  43. (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
  44. (2001). Self-reported quality of life across mood states in bipolar disorder.
  45. (1999). Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defi ned population with type 2 diabetes mellitus. Clin Ther,
  46. (2005). The dosing of atypical antipsychotics.
  47. (1997). The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med,
  48. (2004). The prevalence of the metabolic syndrome in patients with schizoaffective disorder – bipolar subtype. Bipolar Disord,
  49. (2005). The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.
  50. (2006). Treatment resistant bipolar depression. A STEP-BD equipoise randomized effectiveness trail of antidepressant augmentation with lamotrigine, inositol or risperidone.
  51. (2006). URL: http://www.psych.org

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.